不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
DLBCL 肿瘤免疫微环境中的免疫检查点表达：临床病理特征与预后
英文原题：The immune checkpoint expression in the tumor immune microenvironment of DLBCL: Clinicopathologic features and prognosis.
查看英文原题
The immune checkpoint expression in the tumor immune microenvironment of DLBCL: Clinicopathologic features and prognosis.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
TIM-3 的表达水平与 Ann-Arbor 分期密切相关，有望成为评估 DLBCL 侵袭性的新指标。PD-1 与 LAG-3 的表达相关，LAG-3 及 LAG-3/PD-1 高表达预示 DLBCL 预后不良。因此，LAG-3 可能成为免疫治疗的新靶点，或与 PD-1 抑制剂联合使用以改善当前 DLBCL 患者的耐药性。
研究思路结论见上方概要
目的
免疫检查点近来为恶性肿瘤的免疫治疗提供了新策略。然而，其在DLBCL免疫微环境中的作用尚不完全清楚。
方法
我们通过IHC检测了174例DLBCL患者TILs和肿瘤细胞上PD-1、LAG-3、TIM-3和TIGIT的表达。
结果
在TILs中，PD-1、LAG-3、TIM-3和TIGIT的阳性率分别为79.3%、78.8%、62.7%和69.5%。TIM-3和TIGIT在44.8%和45.4%的肿瘤细胞中表达。TILs中TIM-3的表达与Ann-Arbor分期显著相关（P=0.039）。PD-1与LAG-3或TIM-3与TIGIT之间存在正相关。此外，TILs中LAG-3的表达与较差预后相关。多因素分析显示，PS评分和R-CHOP治疗是DLBCL患者OS和PFS的独立危险因素（P=0.000）。
展开英文摘要原文
METHODS
We detected the expression of PD-1, LAG-3, TIM-3, and TIGIT on TILs and on tumor cells among 174 DLBCL patients by IHC.
RESULTS
In TILs, the positive rates of PD-1, LAG-3, TIM-3 and TIGIT were 79.3%, 78.8%, 62.7% and 69.5%, respectively.TIM-3 and TIGIT were expressed in 44.8% and 45.4% of tumor cells. The expression of TIM-3 in TILs was significantly correlated with the Ann-Arbor stage (P=0.039). There was a positive correlation Between PD-1 and LAG-3 or TIM-3 and TIGIT.In addition, LAG-3 expression in TILs was associated with inferior prognosis.Multivariate analysis showed that PS score and R-CHOP therapy were independent risk factors for OS and PFS in patients with DLBCL (P=0.000).
CONCLUSIONS
The expression level of TIM-3 is closely related to the Ann-Arbor stage, which may be expected to be a new index to evaluate the invasiveness of DLBCL. PD-1 was correlated with the expression of LAG-3, and the high expression of LAG-3 and LAG-3/PD-1 predicted the poor prognosis of DLBCL. Therefore, LAG-3 may become a new target of immunotherapy, or be used in combination with PD-1 inhibitors to improve the drug resistance of current patients with DLBCL.
论文信息
- 作者
- Ma J、Pang X、Li J、Zhang W、Cui W
- 单位
- Department of Pathology, The First Affiliated Hospital, Xinjiang Medical University, Xinjiang, Urumqi, China.China
- 期刊
- Frontiers in oncology2022
- 原文标识
- PubMed 36561512 · DOI 10.3389/fonc.2022.1069378
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →